Star Imaging And Path Lab Limi Share Price & Stock Analysis

Star Imaging And Path Lab Limi (BSE: 544482) is a New Delhi, Delhi-based company in the Medical Diagnostic Centres industry. With a market capitalisation of ₹119 Cr, it ranks #3,111 by market cap among the 6,197 Indian listed companies on FinBizNet, and #10 of 18 in Medical Diagnostic Centres. At ₹67.00 (as of 16 Nov 2026), the share price is 52.8% below its 52-week high of ₹141.80 and 45.7% above its 52-week low of ₹46.00. The share price is down 51.5% over one year and down 31.3% over three months.

Key Metrics

Current Price₹67.00
Market Cap₹119 Cr
BSE Code544482
SectorHealth Care > Health Care Equipment and Services > Health Care Providers and Services
Sub-IndustryHealth Care Services > Medical Diagnostic Centres
P/E Ratio6.1
Return on Assets13.52%
52-Week Range₹46.00 – ₹141.80
1-Year Price Change-51.5%
3-Month Price Change-31.3%
Beta (1Y)0.48
HeadquartersNew Delhi, Delhi
Websitewww.starimaging.in

Shareholding and Delivery

Delivery averaged 96.6% of traded volume across 15 BSE sessions (21 Oct 2026 – 13 Nov 2026).

About Star Imaging And Path Lab Limi

Star Imaging and Path Lab Limited operates as a diagnostic testing network and provides diagnostic imaging services and clinical laboratory tests in India. It offers diagnostic and radiology services, which includes X-rays, computed tomography (CT) scans, magnetic resonance imaging (MRI) scans, 4D and 5D ultrasounds, bone mineral densitometry, mammography, and orthopantomogram, surgical/anatomic pathology; pathology services, includes hematology, polymerase chain reaction, clinical pathology, histopathology, cytopathology, treadmill stress test, echocardiogram, microbiology, serology, cytology, immunology and bio chemistry, electrocardiogram, and immunology, holter monitoring, electroencephalogram, visual evoked potential, nerve conduction velocity, brainstem evoked response audiometry, electromyography, sleep study, pulmonary function test, fibro scan, and uroflowmetry; and other specialized testing services. It also provides Dexa scan, colour doppler, neurology, fetal echocardiograph

Products and Services

1. Diagnostic Centre-This segment operates as a diagnostic testing network and provides diagnostic imaging services and clinical laboratory tests. 2. NA-NA 3. NA-NA 4. NA-NA

Business Segments

1. Diagnostic Centre-100%

Star Imaging And Path Lab Limi vs Peers — Medical Diagnostic Centres

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Dr. Lal Pathlabs Ltd₹33,934 Cr66.421.48%₹874 Cr+28.7%
Vijaya Diagnostic Centre Limited₹14,665 Cr84.319.70%₹255 Cr+38.5%
Metropolis Healthcare Limited₹11,952 Cr61.513.37%₹497 Cr+14.9%
Throcare Technologies Ltd₹7,764 Cr47.628.74%₹271 Cr+7.5%
SURAKSHA DIAGNOSTIC LIMITED₹1,856 Cr55.413.84%₹99 Cr+6.9%
Krsnaa Diagnostics Ltd₹1,625 Cr16.810.89%₹271 Cr-27.0%
Gaudium IVF and Women Health Limited₹803 Cr27.416.08%₹37 Cr—
Chandan Healthcare Limited₹582 Cr21.918.43%₹81 Cr—
Star Imaging And Path Lab Limi₹119 Cr6.1——-51.5%

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of Star Imaging And Path Lab Limi?

Star Imaging And Path Lab Limi is trading at ₹67.00, with a market capitalisation of ₹119 Cr.

Which sector does Star Imaging And Path Lab Limi belong to?

Star Imaging And Path Lab Limi operates in the Health Care > Health Care Equipment and Services > Health Care Providers and Services space (Health Care Services > Medical Diagnostic Centres).

What are the key financial ratios of Star Imaging And Path Lab Limi?

Star Imaging And Path Lab Limi has a P/E of 6.1.

What is the stock symbol of Star Imaging And Path Lab Limi?

Star Imaging And Path Lab Limi is listed on the BSE under the scrip code 544482.

How has Star Imaging And Path Lab Limi's share price moved over the past year?

Star Imaging And Path Lab Limi's share price is down 51.5% over one year and down 31.3% over three months. Its 52-week range is ₹46.00 to ₹141.80.

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.